Hepatitis B
355 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by VHCFrankfurt
Scoop.it!

Hepatitis B Screening Proposed for All High-Risk Adults - MedicineNet

Hepatitis B Screening Proposed for All High-Risk Adults - MedicineNet | Hepatitis B | Scoop.it

Adults at high risk for hepatitis B should be screened for the viral infection, according to a draft recommendation from the U.S. Preventive Services Task Force.

more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Tekmira stops work on Ebola drug and will change name to Arbutus as it focuses on hepatitis B

Tekmira stops work on Ebola drug and will change name to Arbutus as it focuses on hepatitis B | Hepatitis B | Scoop.it
From BioPortfolio: One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its nam...
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015

Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015 | Hepatitis B | Scoop.it
Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Mother-to-child transmission of hepatitis B virus in Africa: is elimination feasible? - SACEMA Quarterly

Mother-to-child transmission of hepatitis B virus in Africa: is elimination feasible? - SACEMA Quarterly | Hepatitis B | Scoop.it
Birth dose HBV vaccine, increasing coverage of HBV vaccine and ART could lead to eradication of HBV MTCT in Africa.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Hepatitis B Vaccine Discontinued After Three Newborn Babies Die

Hepatitis B Vaccine Discontinued After Three Newborn Babies Die | Hepatitis B | Scoop.it
Three babies in Vietnam died after receiving their hepatitis B vaccine, prompting the health department to discontinue the use of two entire vaccine lots.
more...
No comment yet.
Rescooped by VHCFrankfurt from Virology News
Scoop.it!

WHO urges stepped-up battle against hepatitis B

WHO urges stepped-up battle against hepatitis B | Hepatitis B | Scoop.it
The world can beat the liver-attacking hepatitis B virus, which results in some 650.000 deaths a year, the World Health Organization said Thursday, releasing its first treatment guidelines for the disease.

Via Ed Rybicki
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics… | hepbblog

Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics… | hepbblog | Hepatitis B | Scoop.it
RT @HepBFoundation: Newly diagnosed with #hepatitis B? Acute? Chronic? Learning the #HBV basics http://t.co/sm6MEeBVRx #hepatitisB
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Mylan Launches Generic Hepatitis B Treatment - Drug Discovery & Development

Mylan Launches Generic Hepatitis B Treatment - Drug Discovery & Development | Hepatitis B | Scoop.it
Mylan Inc. announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's Epivir-HBV. Mylan received final approval from the U.S.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data - TheStreet.com

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data - TheStreet.com | Hepatitis B | Scoop.it
Adam Feuerstein's biotechnology blog, Biotech Beat, features Adam's opinion and analysis on an array of biotech and pharmaceutical stocks and companies.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Arrowhead Discloses First Human Hepatitis B Therapy Results - TheStreet.com

Arrowhead Discloses First Human Hepatitis B Therapy Results - TheStreet.com | Hepatitis B | Scoop.it
Arrowhead Discloses First Human Hepatitis B Therapy Results
TheStreet.com
Arrowhead says educated guesses are being made based on the blinded responses.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Biochemist's work helps new company focus on potential hepatitis B cure - Phys.Org

Biochemist's work helps new company focus on potential hepatitis B cure - Phys.Org | Hepatitis B | Scoop.it
Phys.Org Biochemist's work helps new company focus on potential hepatitis B cure Phys.Org An Indiana University biochemist's discovery of a class of anti-viral small molecules that target the function of a virus DNA hidden in the infected livers of...
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Hepatitis B infections in Kenya surpass HIV - The Standard Digital News

The Standard Digital News
Hepatitis B infections in Kenya surpass HIV
The Standard Digital News
NAIROBI, KENYA: The rate of Hepatitis B virus (HBV) infection in the country is currently three times higher than that of HIV, a study has revealed.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Govt Urged to Give Hepatitis B Increased Priority - AllAfrica.com

Govt Urged to Give Hepatitis B Increased Priority AllAfrica.com In a bid to increase awareness on the prevention, management and treatment of hepatitis B in the country, stakeholders in the health sector have called on the Ministry of Health to...
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520

Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520 | Hepatitis B | Scoop.it
Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Ichor and Janssen to collaborate on Hepatitis B therapy

Ichor Medical Systems has announced that it has entered into a product development collaboration and worldwide license agreement with Janssen.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

WHO urges stepped-up battle against hepatitis B

WHO urges stepped-up battle against hepatitis B | Hepatitis B | Scoop.it
The world can beat the liver-attacking hepatitis B virus, which results in some 650.000 deaths a year, the World Health Organization said Thursday, releasing its first treatment guidelines for the disease.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Grisel buys DVAX 22.43: Dynavax The Superior Player In Hepatitis B Vaccination ...

Grisel buys DVAX 22.43: Dynavax The Superior Player In Hepatitis B Vaccination ... | Hepatitis B | Scoop.it
"Earlier this week the Data and Safety Monitoring Board (DSMB) completed its second review for Heplisav, DVAX’s (NASDAQ: DVAX) Phase 3 hepatitis B vaccin," said Tilda to Luz on Tuesday, March 17,...
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

WHO | Hepatitis B

Hepatitis B: WHO fact sheet on Hepatitis B providing key facts and information on geographical distribution, transmission, who is at risk, treatment, prevention, WHO response
more...
No comment yet.
Rescooped by VHCFrankfurt from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Alnylam Pharmaceuticals, Inc. - Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs"

Alnylam Pharmaceuticals, Inc. - Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs" | Hepatitis B | Scoop.it

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today its pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease. The new strategy builds on the company's progress in the advancement of RNAi therapeutics, including its "Enhanced Stabilization Chemistry" (ESC)-GalNAc conjugate technology, as a modular and reproducible platform for discovery of innovative medicines. Alnylam's STArs will remain focused on liver-expressed and genetically validated or pathogen-derived disease targets, with biomarkers for assessment of clinical activity early in Phase 1 trials. The company will be discussing its STAr pipelines, recent progress, and plans for the future at a webcast R&D Day it is hosting in New York City today. InJanuary 2015, the company expects to provide additional specific guidance on pipeline programs in its three STArs.

 

In its Genetic Medicine STAr, Alnylam is advancing a broad pipeline of RNAi therapeutics for rare diseases. This pipeline includes patisiran and revusiran, investigational RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis (ATTR), that are now in Phase 3 clinical trials with the company's APOLLO and ENDEAVOUR studies, respectively. 

 

In its Cardio-metabolic Disease STAr, Alnylam is advancing its pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in dyslipidemias, hypertension, non-alcoholic steatohepatitis (NASH), and type 2 diabetes.

 

Finally, in its Hepatic Infectious Disease STAr, Alnylam is advancing a pipeline of RNAi therapeutics that address major global health challenges, including hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, amongst other hepatic infectious disease opportunities. Alnylam is advancing ALN-HBV as a lead program in this STAr, and is announcing today that it has selected a Development Candidate (DC) for the program. The ALN-HBV DC is an ESC-GalNAc-siRNA targeting the HBV genome

 


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 15, 2014 4:48 AM

GalNAc-siRNA conjugates are a proprietary Alnylam delivery platform and are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor. Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology enables subcutaneous dosing with increased potency and durability, and a wide therapeutic index. This delivery platform is being employed in several of Alnylam's genetic medicine programs, including programs in clinical development.

About RNAi

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

 

 

 

 

R&D Day Review/webcast

 

Expands Efforts on Pipeline Development and Commercialization in Genetic Medicine,

Cardio-Metabolic Disease, and Hepatic Infectious Disease STArs -

- Announces Updated Guidance to File Clinical Trial Application for ALN-AS1,

an Investigational RNAi Therapeutic for Hepatic Porphyrias, by End-2014 -

- Selects Potent Development Candidate for ALN-HBV, Showing Up to 3.9 Log10

Knockdown of Hepatitis Surface Antigen (HBsAg) after

Single Subcutaneous Dose in Rodent Model of HBV Infection -

- Company to Webcast its R&D Day Today -

Scooped by VHCFrankfurt
Scoop.it!

Doctors urge men over 45 to have check for Hepatitis B - AsiaOne

Doctors urge men over 45 to have check for Hepatitis B - AsiaOne | Hepatitis B | Scoop.it
AsiaOne
Doctors urge men over 45 to have check for Hepatitis B
AsiaOne
SINGAPORE - Doctors are calling for men over 45 to get themselves checked for Hepatitis B, as the virus is often a precursor to liver cancer.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Miracle drug for Hepatitis B? - CNBC

Miracle drug for Hepatitis B? - CNBC | Hepatitis B | Scoop.it
Chris Anzalone, Arrowhead Research president and CEO, discusses a breakthrough in the search for a cure to Hepatitis B.
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

The China GAVI Project

RT @GAVISeth: Did you know? From 2002-2011 @GAVIAlliance worked w/ #China to help expand #hepatitis B vax coverage http://t.co/1m27SwH0TF
more...
No comment yet.
Scooped by VHCFrankfurt
Scoop.it!

Health Department addresses hepatitis B issue

Health Department addresses hepatitis B issue | Hepatitis B | Scoop.it
Health Department addresses hepatitis B issue (HBV Advocate Blog: #hepatitisB Health Department addresses hepatitis B issue http://t.co/2mtqYycxLJ)
more...
No comment yet.